Search hospitals > Tennessee > Memphis
Baptist Memorial Hospital and Cancer Center-Memphis
Claim this profileMemphis, Tennessee 38120
Global Leader in Lung Cancer
Global Leader in Skin Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
185 reported clinical trials
33 medical researchers
Summary
Baptist Memorial Hospital and Cancer Center-Memphis is a medical facility located in Memphis, Tennessee. This center is recognized for care of Lung Cancer, Skin Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. Baptist Memorial Hospital and Cancer Center-Memphis is involved with conducting 185 clinical trials across 396 conditions. There are 33 research doctors associated with this hospital, such as Philip E. Lammers, Raymond U. Osarogiagbon, Salil Goorha, and Stephen W. Behrman.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage III
2Skin Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Philip E. LammersBaptist Memorial Hospital and Cancer Center-Memphis5 years of reported clinical research
Studies Breast Cancer
Studies Lung Cancer
20 reported clinical trials
35 drugs studied
Raymond U. OsarogiagbonBaptist Memorial Hospital and Cancer Center-Memphis6 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
29 drugs studied
Salil GoorhaBaptist Memorial Hospital and Cancer Center-Memphis5 years of reported clinical research
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Lymphoma
9 reported clinical trials
31 drugs studied
Stephen W. BehrmanBaptist Memorial Hospital and Cancer Center-Memphis5 years of reported clinical research
Studies Pancreatic Cancer
Studies Uterine Tumors
7 reported clinical trials
20 drugs studied
Clinical Trials running at Baptist Memorial Hospital and Cancer Center-Memphis
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Breast cancer
Skin Cancer
Pancreatic Cancer
Acute Myeloid Leukemia
Gallbladder Cancer
Cancer
Small Cell Lung Cancer
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Baptist Memorial Hospital and Cancer Center-Memphis?
Baptist Memorial Hospital and Cancer Center-Memphis is a medical facility located in Memphis, Tennessee. This center is recognized for care of Lung Cancer, Skin Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. Baptist Memorial Hospital and Cancer Center-Memphis is involved with conducting 185 clinical trials across 396 conditions. There are 33 research doctors associated with this hospital, such as Philip E. Lammers, Raymond U. Osarogiagbon, Salil Goorha, and Stephen W. Behrman.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.